ABEO
ABEONA THERAPEUTICS INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 16 ▼ 1 insider sell $3.7K at $4.76
- Mar 31 ▼ 1 insider sell $131.5K at $4.38
- May 11 to May 22 ▼ 3 days of insider sells: $213.2K by 3 insiders, avg $5.58
- Jun 8 to Jun 15 ▼ 3 days of insider sells: $782.1K by 5 insiders, avg $5.41
- Jun 30 ▼ 1 insider sell $65.1K at $5.92
- Jul 9 ▼ 4 insiders sell $818.3K at $6.96
- Jul 21 ▼ 1 insider sell $9.7K at $6.53
- Sep 1 ▼ 1 insider sell $88.0K at $5.86
- Sep 17 Roth Capital initiates
- Sep 29 ▼ 4 insiders sell $208.4K at $5.16
- Nov 9 ▼ Abeona Therapeutics entered into a securities purchase agreement wit…
- Nov 9 M&A: Abeona Therapeutics® Acquires Phase 3-Ready APT-1011, Now…
- Nov 13 New insider trade: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersLOCKED
1 open-market trade filed or updated in the last 24 hours. 🔒 Subscribers only.
- InstitutionsMIXED
Q3 2026: 15 added (0 new), 11 trimmed or exited.
- AnalystsBULLISH
12 of 13 rate it Buy or better. Every target is above the price.
- EstimatesFALLING
Current-quarter EPS estimate −$0.110 → −$0.170 over 90 days.
- Short sellersSTEADY
Short interest −1.9% to 16.88M shares. 21.7 days to cover, ≈29.5% of shares.
- TrendDOWNTREND
44% below its 50-day average. New closing low $2.29 on Nov 12.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 29.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| CITIGROUP INC | ADD | $4.6M |
| BARCLAYS PLC | ADD | $3.2M |
| PANAGORA ASSET MANAGEMENT INC | ADD | $2.8M |
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | $1.0M |
| AMERICAN CENTURY COMPANIES INC | ADD | $388.8K |
| BNP PARIBAS FINANCIAL MARKETS | DOUBLED | $367.1K |
| FMR LLC | TRIM | $217.6K |
| Creative Planning | ADD | $150.9K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
13 analystsPrice is below the lowest target. Median implies +496%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 12, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Nov 9, 2026 | Cantor Fitzgerald MAINTAIN | Overweight |
| Sep 18, 2026 | Cantor Fitzgerald MAINTAIN | Overweight |
| Sep 17, 2026 | Roth Capital INITIATE | Buy |
| Aug 14, 2026 | Oppenheimer MAINTAIN | Outperform |
| May 28, 2026 | HC Wainwright & Co. REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
| 🔒 Fresh data, subscribers only Nov 13, 2026 | BUY | |
Vasanthavada Madhav Chief Commercial Officer Sep 29, 2026 | SELL | $25.3K |
O'Malley Brendan M. SVP, Chief Legal Officer Sep 29, 2026 | SELL | $34.7K |
Vazzano Joseph Walter Chief Financial Officer Sep 29, 2026 | SELL | $47.4K |
Seshadri Vishwas Chief Executive Officer Sep 29, 2026 | SELL | $101.1K |
Alvino Mark Director Sep 1, 2026 | SELL | $88.0K |
Vazzano Joseph Walter Chief Financial Officer Jul 21, 2026 | SELL | $9.7K |
O'Malley Brendan M. SVP, Chief Legal Officer Jul 9, 2026 | SELL | $83.9K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.17 | -$0.25–-$0.05 | -27.5% | $12.6M |
| Next Q | -$0.22 | -$0.24–-$0.16 | -72.5% | $12.9M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
24 filings · 5 press releases · 2 bullish · 4 bearish · 1 mixed · 17 neutral- NEUTRAL SC 13GNov 16, 2026
TPG GP A, LLC filed a Schedule 13G disclosing a 7.0% passive stake in Abeona Therapeutics as of November 6, 2026. The stake of 4,761,050 shares is held through entities related to the Ellodi Pharmaceuticals asset acquisition and a PIPE financing.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 13, 2026
Funicular Funds, LP filed an amended Schedule 13G disclosing a 7.5% passive stake in Abeona…
Monitor for any future conversion to a 13D filing, which would signal activist intent. The stake increase suggests growing conviction but remains passive for now.
- NEUTRAL SC 13G/ANov 12, 2026
Daniel Kaufman filed an amended Schedule 13G disclosing a 7.3% passive stake in Abeona…
Monitor for any future conversion to a 13D filing, which would signal activist intent. The recent 8-K earnings filing (Nov 9) provides context for evaluating the investment thesis.
- NEUTRAL PRESS-RELEASENov 9, 2026
Abeona Therapeutics reported Q3 2026 net ZEVASKYN revenue of $13.5M, up 18% sequentially, with a…
Monitor ZEVASKYN treatment volume and QTC activation pace in Q4, as revenue growth depends on batch release consistency and hospital adoption. The PIPE and asset acquisition add dilution risk but…
All ABEO filing & press-release reports (29)
- SC 13G reportNov 16, 2026
- SC 13G/A reportNov 13, 2026
- SC 13G/A reportNov 12, 2026
- PRESS-RELEASE reportNov 9, 2026
- PRESS-RELEASE reportNov 9, 2026
- 8-K reportNov 9, 2026
- INST-CLUSTER reportNov 6, 2026
- SC 13D reportOct 23, 2026
- CLUSTER reportSep 29, 2026
- PRESS-RELEASE reportSep 18, 2026
- 8-K reportSep 15, 2026
- INST-CLUSTER reportAug 14, 2026
- PRESS-RELEASE reportAug 13, 2026
- 8-K reportAug 13, 2026
- CLUSTER reportJul 9, 2026
- CLUSTER reportJun 15, 2026
- CLUSTER reportJun 15, 2026
- 8-K reportJun 12, 2026
- 8-K reportJun 10, 2026
- CLUSTER reportJun 9, 2026
- 8-K reportJun 4, 2026
- CLUSTER reportMay 22, 2026
- PRESS-RELEASE reportMay 13, 2026
- 8-K reportMay 13, 2026
- DEFA14A reportMay 4, 2026
- 8-K reportApr 7, 2026
- PRESS-RELEASE reportApr 2, 2026
- PRESS-RELEASE reportMar 17, 2026
- PRESS-RELEASE reportMar 3, 2026